Knight Therapeutics (OTCMKTS:KHTRF) Trading 0.5% Higher – Should You Buy?

Knight Therapeutics Inc. (OTCMKTS:KHTRF) was up 0.5% during trading on Tuesday . The stock traded as high as $4.1920 and last traded at $4.1920. Approximately 2,300 shares traded hands during trading, a decline of 10% from the average daily volume of 2,548 shares. The stock had previously closed at $4.1720.

Knight Therapeutics Trading Up 0.5%

The firm has a fifty day moving average price of $4.44 and a 200 day moving average price of $4.40.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.